| |
 |
Editorial [Hot Topic: Recombinant Immunotoxins – The Next Generation (Executive Editor: Stefan Barth)]
|
| |
|
pp.2650-2651 (2) Author: Stefan Barth
|
| |
|
|
| |
|
Recombinant Immunotoxins for the Treatment of Chemoresistant Hematologic Malignancies
|
| |
|
pp.2652-2664 (13) Author: Robert J. Kreitman
|
| |
|
|
| |
|
Ribonucleases and ImmunoRNases as Anticancer Drugs
|
| |
|
pp.2665-2675 (11) Authors: S. M. Rybak, M. A.E. Arndt, T. Schirrmann, S. Dubel, J. Krauss
|
| |
|
|
| |
|
Development of Novel, Highly Cytotoxic Fusion Constructs Containing Granzyme B: Unique Mechanisms and Functions
|
| |
|
pp.2676-2692 (17) Authors: M. G. Rosenblum, S. Barth
|
| |
|
|
| |
|
Immunokinases, a Novel Class of Immunotherapeutics for Targeted Cancer Therapy
|
| |
|
pp.2693-2699 (7) Authors: Mehmet Kemal Tur, Inga Neef, Gernot Jager, Andreas Teubner, Michael Stocker, Georg Melmer, Stefan Barth
|
| |
|
|
| |
|
Improved Immunotoxins with Novel Functional Elements
|
| |
|
pp.2700-2711 (12) Authors: C. Hetzel, C. Bachran, M K. Tur, H. Fuchs, M. Stocker
|
| |
|
|
| |
|
Fcγ Receptor 1 (CD64), a Target Beyond Cancer
|
| |
|
pp.2712-2718 (7) Authors: T. Thepen, M. Huhn, G. Melmer, M. K. Tur, S. Barth
|
| |
|
|
| |
|
Targeting Phosphatidylserine in Anti-Cancer Therapy
|
| |
|
pp.2719-2723 (5) Authors: Heidi Kenis, Chris Reutelingsperger
|
| |
|
|
| |
|
Nanocarriers in Ocular Drug Delivery: An Update Review
|
| |
|
pp.2724-2750 (27) Authors: Sheetu Wadhwa, Rishi Paliwal, Shivani Rai Paliwal, S. P. Vyas
|
| |
|
|
| |
|
Vitamin D Deficiency: The Invisible Accomplice of Metabolic Endotoxemia?
|
| |
|
pp.2751-2758 (8) Authors: Paul Lee, Lesley V. Campbell
|
| |
|
|
